The Conversation theconversation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theconversation.com Daily Mail and Mail on Sunday newspapers.
Share:
Extended safety analysis across eight studies helps further define the known safety profile of Olumiant 2-mg in atopic dermatitis
TORONTO, April 30, 2021 /CNW/ - Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company and Incyte s Olumiant® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate- to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, Olumiant provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by per cent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with Olumiant showed significant improvements in the severity and extent of disease comp
TORONTO Health Canada is warning about the potential risk of treatment failure for a Canadian-made COVID-19 monoclonal antibody, saying it may not protect against infection from some variants.
In a statement issued on Wednesday, Health Canada said that bamlanivimab may fail to treat certain variants of SARS-CoV-2, the virus which causes COVID-19. The agency said the potential risk was identified through global surveillance. The agency said the antibody treatment is expected to retain clinical benefit against the B.1.1.7 variant, which was first identified in the United Kingdom. However, Health Canada is advising health-care professionals that bamlanivimab exhibited reduced activity against SARS-CoV-2 variants with the E484K and L452R mutations.
Canadian-made COVID-19 antibody treatment sitting on shelves due to lack of administration plan kake.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kake.com Daily Mail and Mail on Sunday newspapers.
TORONTO A Canadian-made COVID-19 antibody treatment is sitting on hospital and pharmacy shelves amid the countryâs third wave of the pandemic because doctors say a plan on how to administer the drug was never made. âIt s actually very frustrating that we have a therapy available to us that we re not actually able to use,â said infectious disease expert Dr. Deepali Kuma. Bamlanivimab is a monoclonal antibody directed against the spike protein of SARS-CoV-2, the virus that causes COVID-19. The drug mimics the immune system s ability to fight off the virus and was developed by AbCellera Biologics Inc. in Vancouver with the support of the federal government, which had committed up to $175.6 million to the company in May 2020 to develop antibody therapies.